Gilead to present data on anito-cel, Yescarta at ASH meeting
Gilead Sciences (GILD) and its subsidiary Kite will present data on anito-cel and Yescarta at the ASH meeting in December 2026. The data includes 18-month follow-up on anito-cel for multiple myeloma and 5-year follow-up on Yescarta for lymphoma. Anito-cel is under FDA review with a decision expected December 23, 2026. The company also announced data on investigational gamgertamig for autoimmune diseases.
How this was made
The 30-second read
Why it matters
The disclosed data provide the first public readout of anito-cel efficacy and safety, informing the pending BLA and potential market launch.
Market read
New clinical data are a material catalyst for GILD, likely influencing short‑term price action and longer‑term valuation.
What to watch
Regulatory timeline and reimbursement landscape could limit upside despite positive data.
Background
Gilead's Kite unit is a leading developer of CAR‑T therapies; the ASH meeting is a key venue for oncology data releases.
Ticker impact
Gilead Sciences will present Phase 2 data on anito-cel and five-year Yescarta data at the ASH meeting, with the data forming the basis of a pending BLA under FDA review.
likely upward pressure as market prices in the new efficacy data
Phase 2 data for a CAR‑T candidate and long‑term Yescarta outcomes are material catalysts for a biotech with an upcoming BLA decision.
Market effects
CAR‑T and bispecific antibody space may see heightened investor interest.
US biotech sector could see modest gains.
International investors tracking oncology pipelines will monitor the data.
Counterpoint
If data are mixed, the hype could fade quickly, leading to short‑term volatility.
Key entities
- companyGilead Sciences
US‑listed biotech presenting trial data.
- subsidiaryKite
Gilead's CAR‑T development unit.
